Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, active control clinical trial to evaluate
the safety and efficacy of a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan),
used independently and in combination, to improve beneficial effect demonstrated by the
active control which is to be injection of autologous bone marrow aspirate concentrate (BMAC)
into an osteoarthritic knee.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Steadman Philippon Research Institute
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)